Fresenius Medical Care Posts 27% Operating Income Gain, Proposes 3% Dividend Hike
Fresenius Medical Care reported 27% full-year operating income growth to EUR 1.83 billion in 2025, driven by 8% organic revenue growth and an 11.3% margin within its mid-term target band. EPS rose 44% to EUR 3.36 on accelerated share buybacks, and a EUR 1.49 dividend (+3%) was proposed for 2025.
1. 2025 Financial Highlights
In 2025, Fresenius Medical Care achieved 8% organic revenue growth to EUR 19.6 billion and delivered 27% operating income growth to EUR 1.83 billion, reaching the top end of its financial outlook. Net income rose 82% to EUR 978 million on a reported basis, while operating margin improved to 11.3% within the mid-term target band.
2. Dividend and Capital Allocation
The board plans to propose a EUR 1.49 dividend per ADR, up 3% year-on-year, supported by an accelerated share buyback program which contributed to a 44% increase in EPS to EUR 3.36. The share repurchase initiative aims to enhance shareholder returns and optimize the capital structure.
3. 2026 Outlook and Strategy
For fiscal 2026, Fresenius Medical Care forecasts operating income to remain at a consistent level despite regulatory and market headwinds, targeting 3–7% CAGR in operating income through 2028. Management will advance its FME Reignite strategy, focusing on profitable growth, core operations strengthening and innovation.
4. FME Reignite and Operational Efficiency
The FME Reignite program includes the large-scale rollout of the 5008X CAREsystem for high-volume hemodiafiltration across U.S. clinics, training over 7,200 clinicians and transitioning 36,000 patients. The FME25+ efficiency initiative delivered EUR 238 million in savings in 2025 and aims to achieve EUR 1.2 billion total savings by 2027.